These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27355392)

  • 1. Clinical relevance for lowering C-reactive protein with statins.
    Arévalo-Lorido JC
    Ann Med; 2016 Nov; 48(7):516-524. PubMed ID: 27355392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.
    Savarese G; Rosano GM; Parente A; D'Amore C; Reiner MF; Camici GG; Trimarco B; Perrone-Filardi P
    Int J Cardiol; 2014 Nov; 177(1):152-60. PubMed ID: 25499365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
    Gortney JS; Sanders RM
    Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein.
    Chan KY; Boucher ES; Gandhi PJ; Silva MA
    Am J Health Syst Pharm; 2004 Aug; 61(16):1676-81. PubMed ID: 15540478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and biomarkers of inflammation.
    Devaraj S; Rogers J; Jialal I
    Curr Atheroscler Rep; 2007 Jan; 9(1):33-41. PubMed ID: 17169243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connecting the role of C-reactive protein and statins in cardiovascular disease.
    Ridker PM
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III39-44. PubMed ID: 12708638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    Shishehbor MH; Patel T; Bhatt DL
    Cleve Clin J Med; 2006 Aug; 73(8):760-6. PubMed ID: 16913201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?
    Akdim F; van Leuven SI; Kastelein JJ; Stroes ES
    Curr Pharm Des; 2007; 13(10):1003-12. PubMed ID: 17430164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.